SG10201508159SA - Factor II And Fibrinogen For Treatment Of Haemostatic Disorders - Google Patents

Factor II And Fibrinogen For Treatment Of Haemostatic Disorders

Info

Publication number
SG10201508159SA
SG10201508159SA SG10201508159SA SG10201508159SA SG10201508159SA SG 10201508159S A SG10201508159S A SG 10201508159SA SG 10201508159S A SG10201508159S A SG 10201508159SA SG 10201508159S A SG10201508159S A SG 10201508159SA SG 10201508159S A SG10201508159S A SG 10201508159SA
Authority
SG
Singapore
Prior art keywords
fibrinogen
factor
treatment
haemostatic disorders
haemostatic
Prior art date
Application number
SG10201508159SA
Other languages
English (en)
Inventor
Ann Lovgren
Kenny Hansson
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44677879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201508159S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of SG10201508159SA publication Critical patent/SG10201508159SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SG10201508159SA 2010-10-06 2011-09-19 Factor II And Fibrinogen For Treatment Of Haemostatic Disorders SG10201508159SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39022410P 2010-10-06 2010-10-06

Publications (1)

Publication Number Publication Date
SG10201508159SA true SG10201508159SA (en) 2015-10-29

Family

ID=44677879

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201508159SA SG10201508159SA (en) 2010-10-06 2011-09-19 Factor II And Fibrinogen For Treatment Of Haemostatic Disorders
SG2013021498A SG188639A1 (en) 2010-10-06 2011-09-19 Factor ii and fibrinogen for treatment of haemostatic disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2013021498A SG188639A1 (en) 2010-10-06 2011-09-19 Factor ii and fibrinogen for treatment of haemostatic disorders

Country Status (16)

Country Link
US (1) US9433664B2 (de)
EP (1) EP2624859B1 (de)
JP (1) JP6000259B2 (de)
KR (1) KR20130136988A (de)
CN (1) CN103221061A (de)
AU (1) AU2011313505B2 (de)
BR (1) BR112013008034A2 (de)
CA (1) CA2812888A1 (de)
DK (1) DK2624859T3 (de)
ES (1) ES2625153T3 (de)
HU (1) HUE033204T2 (de)
MX (1) MX343784B (de)
PL (1) PL2624859T3 (de)
RU (1) RU2606155C2 (de)
SG (2) SG10201508159SA (de)
WO (1) WO2012045569A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2624859B1 (de) 2010-10-06 2017-03-01 Medimmune Limited Faktor ii alleine oder mit anderen faktoren zur behandlung von gestörter hämostase in der dilutionalen blutgerinnungsstörung
IL230150A0 (en) * 2013-12-24 2014-09-30 Omrix Biopharmaceuticals Ltd One-component fibrin glue containing zymogens
KR102658958B1 (ko) 2017-02-09 2024-04-22 체에스엘 베링 게엠베하 출혈의 치료 또는 예방에 사용하기 위한 혈액 응고 인자 대체품
CN116059431A (zh) * 2021-10-29 2023-05-05 丁琴琴 一种含凝血因子的双层止血敷料及其制备方法
WO2023220412A1 (en) * 2022-05-13 2023-11-16 Cedars-Sinai Medical Center Hemostatic monitor

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981002105A1 (en) 1980-01-28 1981-08-06 Baxter Travenol Lab Therapeutic compositions & methods for manufacture and use
US4501731A (en) 1983-06-27 1985-02-26 Tishkoff Garson H Treatment of disparate bleeding disorders with factor X zymogen
DE4430204A1 (de) * 1994-08-26 1996-02-29 Behringwerke Ag Arzneimittel, welches als Gegenmittel für Blut-Antikoagulanzien geeignet ist und seine Verwendung
EP0796623B1 (de) 1996-03-20 2005-05-25 Baxter Aktiengesellschaft Pharmazeutisches Präparat zur Behandlung von Blutgerinnungsstörungen
AT409334B (de) * 1997-09-19 2002-07-25 Immuno Ag Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren
US7094428B2 (en) 2000-06-16 2006-08-22 The University Of Medicine And Dentistry Of New Jersey Hemostatic compositions, devices and methods
US6825323B2 (en) 2001-01-10 2004-11-30 The United States Of America As Represented By The Secretary Of The Army Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
ES2301624T3 (es) 2001-02-05 2008-07-01 Novo Nordisk Health Care Ag Uso combinado de polipeptidos de factor vii y polipeptidos de factor viii.
US20060025336A1 (en) 2001-07-16 2006-02-02 Novo Nordisk A/S Pharmaceutical compositions comprising combinations of factor VII polypeptides and aprotinin polypeptides
AU2002354846B2 (en) * 2001-07-20 2007-08-02 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
US20040101546A1 (en) * 2002-11-26 2004-05-27 Gorman Anne Jessica Hemostatic wound dressing containing aldehyde-modified polysaccharide and hemostatic agents
WO2004060172A1 (en) 2002-12-31 2004-07-22 Marine Polymer Technologies, Inc. Hemostatic compositions and uses therefor
GB0324044D0 (en) * 2003-10-14 2003-11-19 Astrazeneca Ab Protein
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
ES2482105T3 (es) 2004-05-27 2014-08-01 Baxter International Inc. Procedimientos de tratamiento de trastornos hemorrágicos utilizando polisacáridos sulfatados
WO2006114105A2 (en) 2005-04-26 2006-11-02 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
MX2008006313A (es) 2005-11-15 2008-11-06 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
EP1996186A4 (de) * 2006-03-06 2009-07-22 Humagene Inc Verfahren zur herstellung von rekombinantem menschlichen thrombin und fibrinogen
US20080014251A1 (en) 2006-07-14 2008-01-17 Advanced Vascular Dynamics Hemostatic compound and its use
US20090148502A1 (en) 2006-10-23 2009-06-11 Hemo Nanoscience, Llc Compositions and methods for treating lacerations, abrasions, avulsions, burns, ulcers, and cases of excessive bleeding
EP1935429A1 (de) 2006-12-22 2008-06-25 CSL Behring GmbH Synergistische therapeutische Anwendung von Prothrombin-Komplexkonzentraten mit FVIII-Konzentraten
WO2008121330A1 (en) 2007-03-30 2008-10-09 Thrombodyne, Inc. Methods of making concentrated fibrinogen containing compositions and associated systems for preparing fibrin glue
EP2481797A1 (de) 2007-04-13 2012-08-01 Catalyst Biosciences, Inc. Modifizierte Faktor-VII-Polypeptide und Verwendungen dafür
US8852558B2 (en) 2008-03-11 2014-10-07 Materials Modification, Inc. In situ formation of an artificial blockage to control bleeding by polymer expansion with hydrogen peroxide and platinum catalyst
EP2337793A4 (de) 2008-10-08 2013-04-10 Thrombodyne Inc Verfahren zur herstellung von konzentriertem fibrinogen und plättchenhaltigen zusammensetzungen
EP2624859B1 (de) 2010-10-06 2017-03-01 Medimmune Limited Faktor ii alleine oder mit anderen faktoren zur behandlung von gestörter hämostase in der dilutionalen blutgerinnungsstörung

Also Published As

Publication number Publication date
AU2011313505B2 (en) 2015-09-17
WO2012045569A1 (en) 2012-04-12
AU2011313505A1 (en) 2013-04-11
PL2624859T3 (pl) 2017-09-29
CA2812888A1 (en) 2012-04-12
JP2013538863A (ja) 2013-10-17
RU2013120033A (ru) 2014-11-20
MX2013003715A (es) 2013-09-26
US20130280236A1 (en) 2013-10-24
KR20130136988A (ko) 2013-12-13
JP6000259B2 (ja) 2016-09-28
DK2624859T3 (en) 2017-06-06
EP2624859A1 (de) 2013-08-14
MX343784B (es) 2016-11-23
HUE033204T2 (en) 2017-11-28
BR112013008034A2 (pt) 2016-06-14
EP2624859B1 (de) 2017-03-01
SG188639A1 (en) 2013-05-31
CN103221061A (zh) 2013-07-24
WO2012045569A9 (en) 2016-01-07
RU2606155C2 (ru) 2017-01-10
ES2625153T3 (es) 2017-07-18
US9433664B2 (en) 2016-09-06

Similar Documents

Publication Publication Date Title
HK1245130A1 (zh) 酶組合物及其用於創傷愈合的用途
EP2603202A4 (de) Zusammensetzungen und verfahren zur behandlung von tauopathien
EP2533772A4 (de) Verfahren und zusammensetzungen zur wundheilung
ZA201304280B (en) Treatment of jak2-mediated conditions
IL226401A0 (en) Methods for treating disorders related to @fgfBA
EP2554175A4 (de) Zusammensetzung zur bearbeitung beschädigter teiler
IL225130A (en) Devices for treating blood vessels defects
ZA201205829B (en) Treatment of respiratory disorders
ZA201303810B (en) Methods and compositions suitable for promoting healthy skin
EP2654745A4 (de) Zusammensetzung zur behandlung von hautleiden
HK1166305A1 (zh) 用於治療炎症的組合物及方法
GB201302653D0 (en) Pharmaceutical compositions and methods of treatment
EP2574172A4 (de) Materialien und verfahren zur behandlung von entzündungen
IL225793A0 (en) Methods and preparations for curing insulin-related medical conditions
IL256026B (en) Treatment methods
IL225896A0 (en) Treatment of mecp-2 related disorders
EP2566483A4 (de) Verfahren und mittel für verbesserte wundheilung
SG10201508159SA (en) Factor II And Fibrinogen For Treatment Of Haemostatic Disorders
EP2549867A4 (de) Zusammensetzungen und verfahren zur prävention und behandlung von wunden
SG10201510568WA (en) Novel 19-nor-steroids and their use for treating progesterone-dependent conditions
EP2635293A4 (de) Heilungszusammensetzungen für hautwunden und verwendungsverfahren dafür
IL223385B (en) Treatment of inflammatory disorders
EP2654793A4 (de) Verfahren und zusammensetzungen zur wundbehandlung
GB201010638D0 (en) Composition for treatment of skin
GB201007205D0 (en) Treatment of joint disorders